End points in the lepirudin-treated patients compared with controls. (A) Cumulative incidences of the combined end point for the lepirudin-treated patients (dotted line) and the control group (solid line). The end point occurred more frequently in the control group (P = .0281), primarily due to a reduction of new TECs (P = .02). (B) Cumulative incidences of major bleeding for the lepirudin-treated patients (dotted line) and the control group (solid line). Major bleeding occurred more frequently in the study patients (P = .5419).